Jane Street Group LLC Takes $556,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Jane Street Group LLC purchased a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 20,316 shares of the company’s stock, valued at approximately $556,000. Jane Street Group LLC owned 0.07% of Dianthus Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC raised its holdings in Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in Dianthus Therapeutics during the second quarter worth $236,000. SG Americas Securities LLC increased its position in Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after buying an additional 4,506 shares in the last quarter. Fred Alger Management LLC increased its position in Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after buying an additional 3,316 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new position in Dianthus Therapeutics during the second quarter worth $265,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DNTH shares. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer upped their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Finally, TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Up 8.3 %

NASDAQ:DNTH opened at $25.12 on Monday. The business’s 50 day moving average is $24.72 and its two-hundred day moving average is $26.59. Dianthus Therapeutics, Inc. has a 52 week low of $10.65 and a 52 week high of $33.77. The company has a market cap of $743.48 million, a PE ratio of -10.05 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.